A Phase II, Double-Blind RAndomized, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of GW873130 for 10 Days in HIV-1 Infected Adults.
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2008
At a glance
- Drugs Aplaviroc (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 12 Dec 2008 New trial record.